☆ 4.4 Article

Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort

THORACIC CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study

Jun Liu et al.

Summary: This study assessed the use of neoadjuvant camrelizumab plus chemotherapy in patients with resectable esophageal squamous cell carcinoma. The results showed that this treatment approach had promising efficacy and acceptable toxicity, providing an effective option for patients.

INTERNATIONAL JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)

Morihito Okada et al.

Summary: This study reports 3-year follow-up data comparing nivolumab with chemotherapy in previously treated advanced esophageal squamous cell carcinoma patients, showing that nivolumab demonstrated clinically meaningful long-term improvement in overall survival compared with chemotherapy, regardless of the best overall response.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Surgery

Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)

Xiaolong Yan et al.

Summary: This study evaluated the efficacy and safety of tislelizumab combined with chemotherapy as neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma (ESCC). The results showed that this treatment approach had high rates of major pathological response and pathological complete response, and the tolerability was acceptable.

INTERNATIONAL JOURNAL OF SURGERY (2022)

添加到收藏夹

Article Oncology

Sarcopenia and Systemic Inflammation Response Index Predict Response to Systemic Therapy for Hepatocellular Carcinoma and Are Associated With Immune Cells

Man Zhao et al.

Summary: Sarcopenia and high systemic inflammation response index (SIRI) are independently associated with reduced survival in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs). The muscle mass and systemic inflammation levels of patients are closely related to overall survival and progression-free survival, highlighting the importance of considering these factors in treatment.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers

Yingji Wu et al.

Summary: This study developed a nomogram to predict pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) in esophageal squamous cell carcinoma (ESCC) patients by incorporating hematological biomarkers and clinico-pathological characteristics. The nomogram showed good predictive performance, providing valuable insights for treatment decisions.

CANCER RESEARCH AND TREATMENT (2021)

添加到收藏夹

Article Oncology

Usefulness of Neutrophil to Lymphocyte Ratio at Recurrence for Predicting Long-Term Outcomes in Patients with Recurrent Esophageal Squamous Cell Carcinoma

Shota Hoshino et al.

Summary: This study showed that the neutrophil to lymphocyte ratio (NLR) at recurrence is a significant predictor of survival in patients with recurrent esophageal cancer. By using a cut-off value of 3.374 determined by survival classification and regression tree (CART) analysis, NLR can facilitate decision making in clinical practice.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)

Chengqiang Li et al.

Summary: This study investigated the safety and efficacy of preoperative pembrolizumab combined with chemoradiotherapy in resectable oesophageal squamous cell carcinoma patients. The results showed that this treatment was safe and induced a pathological complete response in 55.6% of the tumors.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Cristina Valero et al.

Summary: The study demonstrates the association of higher neutrophil-to-lymphocyte ratio (NLR) with poorer survival outcomes and lower rates of response across multiple cancer types treated with immune checkpoint inhibitors (ICI). Combining NLR with tumor mutational burden (TMB) significantly increases the probability of benefit from ICI, with the low NLR/high TMB group showing the highest likelihood of benefit. These findings highlight the potential of NLR as a cost-effective and widely accessible biomarker for predicting response to ICI therapy.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Factors and Reference Markers of Treatment Options for Locally Advanced Squamous Cell Carcinoma Located in the Middle and Upper Esophagus

Chen Wang et al.

Summary: This study revealed that pretreatment NLR and PLR can serve as independent predictors for patients with locally advanced esophageal squamous cell carcinoma (ESCC) located in the middle or upper esophagus, helping to guide the choice between radical surgery or definitive chemoradiotherapy (dCRT) and being associated with prognosis. Patients with low NLR tend to have better survival outcomes when undergoing surgery.

CANCER MANAGEMENT AND RESEARCH (2021)

添加到收藏夹

Article Oncology

The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma

Dijian Shen et al.

Summary: The study evaluated the efficacy and safety of PD-1 inhibitor in neoadjuvant chemotherapy for locally advanced ESCC, showing a high pCR rate and R0 resection rate with low toxicity. Long-term efficacy of this novel treatment should be confirmed with longer follow-up and prospective trials.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab

Wei-Xiang Qi et al.

Summary: Pre-treatment PLR could serve as an valuable independent prognostic factor for ES-SCLC patients treated with chemotherapy and immune checkpoint inhibitors, with high PLR values associated with significantly poorer survival outcomes.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Immunology

PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients

Ran Zeng et al.

Summary: The study found that high PIV and PILE scores were correlated with worse clinical outcomes in ES-SCLC patients treated with anti-PD-1/PD-L1 inhibitor combined with chemotherapy, suggesting that these factors could be useful in identifying patients unlikely to benefit from such therapy.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

The log odds of negative lymph nodes/T stage: a new prognostic and predictive tool for resected gastric cancer patients

Jiebin Xie et al.

Summary: This study aimed to establish a more effective nomogram based on the log odds of negative lymph nodes/T stage ratio (LONT) to predict survival in surgically treated GC patients. The results showed LONT as an independent prognostic factor for cancer-specific survival and overall survival, with the nomogram model outperforming the TNM staging system in predicting survival.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma

Xianbin Wu et al.

Summary: This study aimed to identify predictors of response to anti-PD-1 therapy in esophageal squamous cell carcinoma (ESCC) patients from peripheral blood parameters. The results showed that a low NLR at 6 weeks post treatment was associated with higher progression-free survival (PFS) rate in ESCC patients, but there was no significant difference in PFS rate based on NLR, PLR, MLR, or SII at baseline or 3 weeks post treatment.

CANCER CELL INTERNATIONAL (2021)

添加到收藏夹

Article Oncology

The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors

Francesca Corti et al.

Summary: The Pan-Immune-Inflammation Value (PIV) proved to be a strong predictor of outcomes in MSI-high mCRC patients receiving ICIs, and both high baseline PIV and early PIV increase were associated with poorer overall survival and progression-free survival. Early PIV increase was identified as an independent predictor of clinical benefit.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong-Mu Sun et al.

Summary: This study aimed to evaluate the antitumor activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced esophageal cancer. Results showed that pembrolizumab plus chemotherapy significantly improved overall survival and progression-free survival in patients with esophageal squamous cell carcinoma.

LANCET (2021)

添加到收藏夹

Article Surgery

Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma The NEOCRTEC5010 Randomized Clinical Trial

Hong Yang et al.

Summary: The study found that neoadjuvant chemoradiotherapy (NCRT) followed by surgery significantly improved long-term overall survival and disease-free survival in patients with locally advanced esophageal squamous cell carcinoma (ESCC).

JAMA SURGERY (2021)

添加到收藏夹

Article Oncology

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab

Matteo Bauckneht et al.

Summary: Identifying reliable prognostic biomarkers for progression and response to immune checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer (NSCLC) is essential. This study combined systemic inflammation indexes and metabolically active tumor burden quantification using FDG PET/CT to predict radiological progression and potential benefit from immunotherapy continuation in NSCLC patients receiving Nivolumab. The combination of these factors in the immune metabolic prognostic index (IMPI) allowed for better risk stratification and clinical management in this patient population.

CANCERS (2021)

添加到收藏夹

Article Oncology

Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram

Peter S. N. van Rossum et al.

PRACTICAL RADIATION ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

Alessio Cortellini et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Article Biology

Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer

Mila P. Petrova et al.

BIOSCIENCE TRENDS (2020)

添加到收藏夹

Article Respiratory System

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab

Taichi Matsubara et al.

JOURNAL OF THORACIC DISEASE (2020)

添加到收藏夹

Article Medicine, General & Internal

Relationship between T stage and survival in distantly metastatic esophageal cancer A STROBE-compliant study

Jianqing Deng et al.

MEDICINE (2020)

添加到收藏夹

Article Oncology

Clinical and prognostic significance of preoperative lymphocyte-monocyte ratio, neutrophil-lymphocyte ratio and neutrophil-monocyte ratio on esophageal squamous cell carcinoma patients

Qi-Xin Shang et al.

TRANSLATIONAL CANCER RESEARCH (2020)

添加到收藏夹

Article Medical Laboratory Technology

Peripheral blood cell count ratios are predictive biomarkers of clinical response and prognosis for non-surgical esophageal squamous cell carcinoma patients treated with radiotherapy

Xiaohui Zhi et al.

JOURNAL OF CLINICAL LABORATORY ANALYSIS (2020)

添加到收藏夹

Article Medicine, General & Internal

Prognostic value of neutrophil-to-lymphocyte ratio in peripheral blood and pathological tissue in patients with esophageal squamous cell carcinoma

Quanquan Guo et al.

MEDICINE (2020)

添加到收藏夹

Article Oncology

Predicting Prognosis and Adverse Events by Hematologic Markers in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy

Guoxin Cai et al.

CANCER MANAGEMENT AND RESEARCH (2020)

添加到收藏夹

Review Cell Biology

PD-L1 degradation pathway and immunotherapy for cancer

Qian Gou et al.

CELL DEATH & DISEASE (2020)

添加到收藏夹

Article Oncology

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

Ugo De Giorgi et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma

Xiaobin Fu et al.

BMC CANCER (2019)

添加到收藏夹

Article Respiratory System

Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab

Taro Ohba et al.

JOURNAL OF THORACIC DISEASE (2019)

添加到收藏夹

Article Oncology

Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors

Fumihiro Shoji et al.

LUNG CANCER (2019)

添加到收藏夹

Article Oncology

The Predictive Value of Pretreatment Neutrophil-To-Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma

Miao-Fen Chen et al.

ANNALS OF SURGICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis

Yugui Sun et al.

CANCER MANAGEMENT AND RESEARCH (2018)

添加到收藏夹

Article Oncology

Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients

Jarrett J. Failing et al.

MELANOMA RESEARCH (2017)

添加到收藏夹

Article Oncology

Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma

Ji-Feng Feng et al.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

P. van Hagen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Oncology

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

Isabelle Ray-Coquard et al.

CANCER RESEARCH (2009)

添加到收藏夹

Review Multidisciplinary Sciences

Cancer-related inflammation

Alberto Mantovani et al.

NATURE (2008)

添加到收藏夹

Article Gastroenterology & Hepatology

Decreased total lymphocyte counts in pancreatic cancer: An index of adverse outcome

P Fogar et al.

PANCREAS (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.